Gamifant marks the first-ever FDA-approved treatment for both adult and pediatric patients with hemophagocytic ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical ...

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions.

Novo Nordisk continues its efforts to promote the use of genuine, FDA approved GLP-1s while combatting the use of compounded alternatives. This has been a uniquely difficult issue in the weight-loss ...

Pharmaceutical Executive: How is federal policy reshaping life sciences investments? John Stanford: Federal policy is ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

Pedro Valencia, VP, asset strategy, leadership, oncology, AbbVie, outlines how the company is accelerating development across ...

Label changes remove Risk Evaluation and Mitigation Strategy programs and eases monitoring requirements, supporting broader ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine explains how insights from the ...

Results from the Phase IIIb FRONTIER5 trial demonstrated that Mim8 prophylaxis was well-tolerated when administered without a ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company partners with patient advocacy groups to identify unmet needs and prioritize patient-centered benefits in the ...